SSTR3 Antibody (YA7309)
(Synonyms: Somatostatin receptor type 3, SS-3-R, SS3-R, SS3R, SST3, SSR-28, SSTR3)SSTR3 Antibody (YA7309) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SSTR3.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, FC
-
Reactivity :
Human
-
Formulation:
Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
FC
FC: Flow Cytometry
|
|---|---|---|
| Dilution Ratio | 1:1000-2000 | 1:50-100 |
Product Details
SSTR3 Antibody (YA7309) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SSTR3.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 70 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 46 kDa
A synthesized peptide derived from human SSTR3
Endogenous
affinity purified by Protein A
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
SSTR3 (somatostatin receptor 3) is a G protein-coupled receptor within the somatostatin receptor family that mediates the cellular actions of somatostatin and is functionally coupled to inhibition of adenylyl cyclase signaling[3][2]. Through regulation of intracellular signaling pathways, SSTR3 contributes to control of neurotransmission, endocrine activity, cell proliferation, and secretory processes, placing it at the intersection of neurobiology and endocrine regulation[3][2]. Mechanistically, activation of SSTR3 can interfere with mitogenic signaling pathways and promote cytostatic or cytotoxic responses, supporting its role in the regulation of cellular growth and survival[1][4]. In disease-related contexts, SSTR3 has been associated with nonfunctioning pituitary adenomas, where receptor activation has demonstrated antitumor effects in experimental models and has been proposed as a biomarker of biological relevance[4][2]. Compared with related somatostatin receptor isoforms, SSTR3 displays distinct pharmacological and regulatory properties, including rapid downregulation following prolonged agonist exposure and functional modulation through receptor heterodimerization, which can alter signaling outcomes[2][5]. This isoform-specific behavior has increased interest in selective ligand development and subtype-targeted research strategies[2][6]. For experimental applications, both SSTR3-selective agonists and antagonists have been developed, enabling investigation of receptor-specific signaling mechanisms, tumor biology, receptor trafficking, and therapeutic targeting in preclinical models[5][6][7].
-
Subcellular Localization
Cell membrane
-
Expression
Tissue_Specificity: Brain, pituitary and pancreas -
Isoforms & Post-Translational Modification
P32745: 418 amino acids, molecular weight 45847 Da.
-
Subunit
Homodimer and heterodimer with SSTR2
-
SwissProt ID
-
Synonyms
Somatostatin receptor type 3, SS-3-R, SS3-R, SS3R, SST3, SSR-28, SSTR3
Documentation
[1]. Modena D, et al. Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas. Cancers (Basel). 2023 Jun 30;15(13):3453. [Content Brief]
[2]. Guccione C, et al. Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations. Comput Struct Biotechnol J. 2024 Mar 18;23:1311-1319. [Content Brief]
[3]. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001;276(17):14027-14036. [Content Brief]
[4]. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998;282(5389):737-740. [Content Brief]
[5]. Poitout L, Roubert P, Contour-Galcera MO, Moinet D, Gondran-Tellier B, et al. Identification of potent non-peptide somatostatin receptor subtype 3 antagonists. J Med Chem. 2001;44(18):2990-3000. [Content Brief]
[6]. Yasuda K, et al. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. Mol Endocrinol. 1992;6(12):2136-2142. [Content Brief]